This HTML5 document contains 77 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n4http://linked.opendata.cz/resource/drugbank/drug/DB00131/identifier/bindingdb/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n8http://linked.opendata.cz/resource/drugbank/drug/DB00131/identifier/pubchem-compound/
n16http://linked.opendata.cz/resource/drugbank/company/
n18http://linked.opendata.cz/resource/drugbank/drug/DB00131/identifier/pubchem-substance/
n11http://linked.opendata.cz/resource/mesh/concept/
n7http://linked.opendata.cz/resource/drugbank/drug/DB00131/identifier/kegg-drug/
n9http://linked.opendata.cz/resource/drugbank/drug/DB00131/identifier/drugbank/
n15http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n23http://linked.opendata.cz/resource/drugbank/drug/DB00131/identifier/chemspider/
n19http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n21http://linked.opendata.cz/resource/drugbank/drug/DB00131/identifier/chebi/
n17http://linked.opendata.cz/resource/drugbank/medicinal-product/
n10http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n5http://linked.opendata.cz/ontology/drugbank/
n6http://linked.opendata.cz/resource/drugbank/property/
n22http://linked.opendata.cz/resource/drugbank/drug/DB00131/identifier/wikipedia/
xsdhhttp://www.w3.org/2001/XMLSchema#
n20http://linked.opendata.cz/resource/drugbank/drug/DB00131/identifier/pharmgkb/
n12http://linked.opendata.cz/resource/drugbank/drug/DB00131/identifier/kegg-compound/

Statements

Subject Item
n2:DB00131
rdf:type
n5:Drug
n5:description
Adenylic acid. Adenine nucleotide containing one phosphate group esterified to the sugar moiety in the 2'-, 3'-, or 5'-position. [PubChem]
n5:group
approved nutraceutical
n5:indication
For nutritional supplementation, also for treating dietary shortage or imbalance
owl:sameAs
n15:DB00131 n19:DB00131
dcterms:title
Adenosine monophosphate
adms:identifier
n4:18137 n7:D02769 n8:6083 n9:DB00131 n12:C00020 n18:46507628 n20:PA164744376 n21:16027 n22:Adenosine_monophosphate n23:5858
n5:mechanismOfAction
Nucleotides such as Adenosine-5'-Monophosphate affect a number of immune functions, including the reversal of malnutrition and starvation-induced immunosuppression, the enhancement of T-cell maturation and function, the enhancement of natural killer cell activity, the improvement of delayed cutaneous hypersensitivity, helping resistance to such infectious agents as Staphylococcus aureus and Candida albicans, and finally the modulation of T-cell responses toward type 1 CD4 helper lymphocytes or Th1 cells. Studies have shown that mice fed a nucleotide-free diet have both impaired humoral and cellular immune responses. The addition of dietary nucleotides normalizes both types of responses. RNA, a delivery form of nucleotides, and ribonucleotides were used in these studies. The mechanism of the immune-enhancing activity of nucleic acids/nucleotides is not clear.
n5:packager
n16:271B48E5-363D-11E5-9242-09173F13E4C5
n5:synonym
Adenosine 5'-monophosphate Adenosini phosphas Phosphate d'adenosine Adenylate AMP 5'-Adenosine monophosphate Adenosine phosphate Adenosine 5'-phosphate 5'-Adenylic acid PAdo Adenosine-5'p Adenosine-5'-monophosphoric acid Adenosine 5'-(dihydrogen phosphate) 5'-O-Phosphonoadenosine ADENOSINE monophosphate Ado5'p Phosaden Fosfato de adenosina Adenylic acid Phosphaden 5'-AMP Adenosine-5'-Monophosphate
n5:synthesisReference
Shigehiro Kataoka, Ayako Nasu, Nobuyuki Yamaji, Motohiko Kato, "Process for preparation of N.sup.6 -substituted 3',5'-cyclic adenosine monophosphate and salt thereof." U.S. Patent US4751293, issued July, 1984.
n10:hasConcept
n11:M0000389
n5:IUPAC-Name
n6:271B48EB-363D-11E5-9242-09173F13E4C5
n5:InChI
n6:271B48F1-363D-11E5-9242-09173F13E4C5
n5:Molecular-Formula
n6:271B48F0-363D-11E5-9242-09173F13E4C5
n5:Molecular-Weight
n6:271B48ED-363D-11E5-9242-09173F13E4C5
n5:Monoisotopic-Weight
n6:271B48EE-363D-11E5-9242-09173F13E4C5
n5:SMILES
n6:271B48EF-363D-11E5-9242-09173F13E4C5
n5:Water-Solubility
n6:271B48E9-363D-11E5-9242-09173F13E4C5 n6:271B4901-363D-11E5-9242-09173F13E4C5
n5:logP
n6:271B48E7-363D-11E5-9242-09173F13E4C5 n6:271B4903-363D-11E5-9242-09173F13E4C5 n6:271B48EA-363D-11E5-9242-09173F13E4C5
n5:logS
n6:271B48E8-363D-11E5-9242-09173F13E4C5
n5:H-Bond-Acceptor-Count
n6:271B48F7-363D-11E5-9242-09173F13E4C5
n5:H-Bond-Donor-Count
n6:271B48F8-363D-11E5-9242-09173F13E4C5
n5:InChIKey
n6:271B48F2-363D-11E5-9242-09173F13E4C5
n5:Polar-Surface-Area--PSA-
n6:271B48F3-363D-11E5-9242-09173F13E4C5
n5:Polarizability
n6:271B48F5-363D-11E5-9242-09173F13E4C5
n5:Refractivity
n6:271B48F4-363D-11E5-9242-09173F13E4C5
n5:Rotatable-Bond-Count
n6:271B48F6-363D-11E5-9242-09173F13E4C5
n5:affectedOrganism
Humans and other mammals
n5:casRegistryNumber
61-19-8
n5:category
n5:containedIn
n17:271B48E6-363D-11E5-9242-09173F13E4C5
n5:Bioavailability
n6:271B48FD-363D-11E5-9242-09173F13E4C5
n5:Ghose-Filter
n6:271B48FF-363D-11E5-9242-09173F13E4C5
n5:MDDR-Like-Rule
n6:271B4900-363D-11E5-9242-09173F13E4C5
n5:Melting-Point
n6:271B4902-363D-11E5-9242-09173F13E4C5
n5:Number-of-Rings
n6:271B48FC-363D-11E5-9242-09173F13E4C5
n5:Physiological-Charge
n6:271B48FB-363D-11E5-9242-09173F13E4C5
n5:Rule-of-Five
n6:271B48FE-363D-11E5-9242-09173F13E4C5
n5:Traditional-IUPAC-Name
n6:271B48EC-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-acidic-
n6:271B48F9-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-basic-
n6:271B48FA-363D-11E5-9242-09173F13E4C5